TLPH Stock Forecast 2025-2026
Distance to TLPH Price Targets
TLPH Price Momentum
10 Quality Stocks Worth Considering Now
Researching AcelRx (TLPH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on TLPH and similar high-potential opportunities.
Latest TLPH Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, TLPH has a bullish consensus with a median price target of $3.50 (ranging from $3.00 to $6.00). Currently trading at $0.56, the median forecast implies a 525.0% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ed Arce at HC Wainwright & Co., projecting a 971.4% upside. Conversely, the most conservative target is provided by Jason McCarthy at Maxim Group, suggesting a 435.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TLPH Analyst Ratings
TLPH Price Target Range
Latest TLPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TLPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 21, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 6, 2024 | Maxim Group | Jason McCarthy | Buy | Initiates | $3.00 |
| Mar 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Jan 22, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $6.00 |
| Dec 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Oct 2, 2023 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| Sep 25, 2023 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Aug 18, 2023 | HC Wainwright & Co. | Buy | Upgrade | $0.00 |
Talphera Inc. (TLPH) Competitors
The following stocks are similar to AcelRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Talphera Inc. (TLPH) Financial Data
Talphera Inc. has a market capitalization of $9.62M with a P/E ratio of -0.4x. The company generates $281,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -5,885.8% and return on equity of -111.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Talphera Inc. (TLPH) Business Model
About Talphera Inc.
Provider of renewable energy solutions.
The company generates revenue by designing, developing, and deploying wind and solar power technologies for both commercial and residential sectors. It also engages in infrastructure projects that modernize energy grids, enhancing the reliability and efficiency of energy distribution.
Talphera Inc. is recognized as a key player in the renewable energy sector, contributing to the global transition towards sustainable energy and reducing carbon footprints. Its commitment to innovation in energy efficiency and storage positions it as a leader in promoting green energy initiatives.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
15
CEO
Mr. Vincent J. Angotti
Country
United States
IPO Year
2011
Website
talphera.comTalphera Inc. (TLPH) Latest News & Analysis
Talphera, Inc. plans to submit a Prior Approval Supplement to the FDA for a reduced patient count in the NEPHRO CRRT study, following protocol changes to speed up enrollment.
FDA approval for protocol changes could speed up the NEPHRO CRRT study, potentially leading to quicker market entry for Talphera's therapies and impacting stock performance.
Talphera, Inc. (NASDAQ:TLPH) will hold its Q3 2024 earnings conference call on November 13, 2024, at 4:30 PM ET, featuring key executives and analysts.
Talphera's Q3 earnings call provides insights into financial performance and strategic direction, impacting stock valuation and investor sentiment. Key executives will discuss results and future plans.
Talphera, Inc. reported $11.1 million in cash and investments as of September 30, 2024. Five sites are screening patients, with two more expected to join soon. A conference call is scheduled for November 13, 2024.
Talphera's active patient screening across multiple sites indicates progress in clinical trials, while $11.1 million in cash suggests financial stability to support ongoing operations and development.
Talphera, Inc. (Nasdaq: TLPH) will release its Q3 2024 financial results on November 13, 2024, after market close, followed by a live webcast at 4:30 p.m.
Talphera's upcoming financial results and conference call can significantly impact stock performance, influencing investor sentiment and expectations for the company's growth and profitability.
Talphera, Inc. (Nasdaq: TLPH) will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will hold 1x1 meetings with registered investors.
Talphera's participation in a major healthcare summit highlights its growth potential and investor engagement, potentially impacting stock interest and market perception.
Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
6 months agoTalphera, Inc. (Nasdaq: TLPH) announced management will participate in the H.C. Wainwright conference, focusing on innovative therapies for medically supervised settings.
Talphera's participation in the H.C. conference could signal upcoming developments or partnerships, potentially impacting stock performance and investor sentiment.
Frequently Asked Questions About TLPH Stock
What is Talphera Inc.'s (TLPH) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Talphera Inc. (TLPH) has a median price target of $3.50. The highest price target is $6.00 and the lowest is $3.00.
Is TLPH stock a good investment in 2025?
According to current analyst ratings, TLPH has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TLPH stock?
Wall Street analysts predict TLPH stock could reach $3.50 in the next 12 months. This represents a 525.0% increase from the current price of $0.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Talphera Inc.'s business model?
The company generates revenue by designing, developing, and deploying wind and solar power technologies for both commercial and residential sectors. It also engages in infrastructure projects that modernize energy grids, enhancing the reliability and efficiency of energy distribution.
What is the highest forecasted price for TLPH Talphera Inc.?
The highest price target for TLPH is $6.00 from Ed Arce at HC Wainwright & Co., which represents a 971.4% increase from the current price of $0.56.
What is the lowest forecasted price for TLPH Talphera Inc.?
The lowest price target for TLPH is $3.00 from Jason McCarthy at Maxim Group, which represents a 435.7% increase from the current price of $0.56.
What is the overall TLPH consensus from analysts for Talphera Inc.?
The overall analyst consensus for TLPH is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are TLPH stock price projections?
Stock price projections, including those for Talphera Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
